Bank of Montreal’s Nautilus Biotechnolgy NAUT Stock Holding History

Bank of Montreal’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,109	Closed	-$33	–	4186
2022 Q3	$33	Buy	+15,109	New	+$38K	﹤0.01%	3719
2022 Q2	–	Sell	-62,000	Closed	-$270K	–	4315
2022 Q1	$270K	Buy	+62,000	New	+$254K	﹤0.01%	3253

Other funds holding NAUT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return

Bank of Montreal's NAUT Position: Q4 2022 in Review

Bank of Montreal sold out of Nautilus Biotechnolgy (NAUT) in Q4 2022, closing a stake of 15,109 shares — an estimated $33 sold.

Bank of Montreal first reported a position in NAUT in Q1 2022 and held it in 2 quarters. The position peaked at $270K in Q1 2022. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2022.

Bank of Montreal reported no remaining Nautilus Biotechnolgy position as of Q4 2022 after selling out during the quarter.
Bank of Montreal sold 15,109 Nautilus Biotechnolgy shares in Q4 2022, an estimated $33.
Bank of Montreal first reported a position in Nautilus Biotechnolgy in Q1 2022 and held it in 2 quarters.
Bank of Montreal's Nautilus Biotechnolgy position peaked at $270K in Q1 2022.
81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2022.

Based on Bank of Montreal's 13F filing for Q4 2022, filed 1 Feb 2023.